On the Record · Biomarin Pharmaceutical
Biomarin Pharmaceutical competitors, on the record
The companies Biomarin Pharmaceutical itself names as competitors in its annual reports, 2023 to 2025, each with the sentence it appears in and the filing it came from.
Who Biomarin Pharmaceutical names
| Company | Named in |
|---|---|
| PTC Therapeutics, Inc. | 2025 |
In its own words
PTC Therapeutics, Inc.
Word for word“PALYNZIQ and KUVAN face competition from an oral small molecule marketed by PTC Therapeutics,Inc., which is approved in the U.S. and EU for the treatment of PKU.” 10-K for 2025
Read from Biomarin Pharmaceutical’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-26. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.